Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P22061

UPID:
PIMT_HUMAN

ALTERNATIVE NAMES:
L-isoaspartyl protein carboxyl methyltransferase; Protein L-isoaspartyl/D-aspartyl methyltransferase; Protein-beta-aspartate methyltransferase

ALTERNATIVE UPACC:
P22061; A8K109; J3KP72; Q14661; Q16556; Q5VYC1; Q5VYC2; Q93061; Q96II9; Q99625; Q9BQV7; Q9BQV8; Q9NP03

BACKGROUND:
The enzyme Protein-L-isoaspartate(D-aspartate) O-methyltransferase, with alternative names such as Protein L-isoaspartyl/D-aspartyl methyltransferase, is pivotal in initiating the repair mechanism for damaged proteins. It targets L-isoaspartyl and D-aspartyl residues in aging proteins, catalyzing methyl esterification. This process is essential for the maintenance and longevity of cellular proteins, affecting key proteins like calreticulin and Ubiquitin C-terminal hydrolase isozyme L1.

THERAPEUTIC SIGNIFICANCE:
The exploration of Protein-L-isoaspartate(D-aspartate) O-methyltransferase's function offers promising avenues for therapeutic intervention. Its critical role in protein repair mechanisms underscores its potential in developing novel strategies to combat diseases associated with protein misfolding and degradation, thereby enhancing cellular resilience and health.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.